Management of breast cancer - Part I

BMJ

Volumn 337, Issue 7661, 2008, Pages 107-110

  Turner, Nicholas C ^a,b   Jones, Alison L ^a,c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE; RALOXIFENE; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ALBERS SCHOENBERG DISEASE; BREAST CANCER; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; ENDOMETRIUM CANCER; ENDOSCOPIC SURGERY; ENVIRONMENTAL EXPOSURE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; MAMMOGRAPHY; MASTECTOMY; MINIMALLY INVASIVE SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SENTINEL LYMPH NODE BIOPSY; STROKE; VENOUS THROMBOEMBOLISM; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; GENETICS; METHODOLOGY; MUTATION; RISK FACTOR; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SURGICAL PROCEDURES, MINIMALLY INVASIVE;

EID: 47649088231     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a421     Document Type: Review

References (30)

1. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822.
2. Michels KB, Mohllajee AP, Roset-Bahmanyar E, Beehler GP, Moysich KB. Diet and breast cancer: a review of the prospective observational studies. Cancer 2007;109(suppl):2712-49.
3. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the women's intervention nutrition study. J Natl Cancer Inst 2006;98:1767-76.
4. Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the women's healthy eating and living (WHEL) randomized trial. JAMA 2007;298:289-98.
5. Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003;362:419-27.
6. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-45.
7. Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007;25:3831-6.
8. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
9. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.
10. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
11. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008;40(1):17-22.
12. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428-37.
13. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA 2001;286:2251-6.
14. Robson M, Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 2007;357:154-62.
15. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159-64.
16. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008;122:2017-22.
17. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2006(4):CD001877.
18. International Agency for Research on Cancer. IARC Handbook of cancer prevention. Volume 7. Breast cancer screening. Lyon, IARC, 2002.
19. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-78.
20. Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 2007;370:485-92.
21. Blumencranz P, Whitworth PW, Deck K, Rosenberg A, Reintgen D, Beitsch P, et al. Scientific impact recognition award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am J Surg 2007;194:426-32.
22. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 2006;98:599-609.
23. Lim SM, Lam FL. Laparoscopic-assisted axillary dissection in breast cancer surgery. Am J Surg 2005;190:641-3.
24. Cunnick GH, Mokbel K. Skin-sparing mastectomy. Am J Surg 2004;188:78-84.
25. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
26. Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. Randomized trial of breast irradiation schedules after lumpectomyfor women with lymph node-negative breast cancer. J Natl Cancer Inst 2002;94:1143-50.
27. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008;371:1098-107.
28. Gebski V, Lagleva M, Keech A, Simes J, Langlands AO. Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. J Natl Cancer Inst 2006;98:26-38.
29. Vaidya JS, Tobias JS, Baum M, Keshtgar M, Joseph D, Wenz F, et al. Intraoperative radiotherapy for breast cancer. Lancet Oncol 2004;5:165-73.
30. Benitez PR, Keisch ME, Vicini F, Stolier A, Scroggins T, Walker A, et al. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg 2007;194:456-62.